Pharmacyte Biotech Stock Alpha and Beta Analysis
| PMCB Stock | USD 0.71 0.06 7.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as PharmaCyte Biotech. It also helps investors analyze the systematic and unsystematic risks associated with investing in PharmaCyte Biotech over a specified time horizon. Remember, high PharmaCyte Biotech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to PharmaCyte Biotech's market risk premium analysis include:
Beta 3.21 | Alpha (0.53) | Risk 9.36 | Sharpe Ratio (0.02) | Expected Return (0.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
PharmaCyte | Build AI portfolio with PharmaCyte Stock |
PharmaCyte Biotech Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. PharmaCyte Biotech market risk premium is the additional return an investor will receive from holding PharmaCyte Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PharmaCyte Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate PharmaCyte Biotech's performance over market.| α | -0.53 | β | 3.21 |
PharmaCyte Biotech expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of PharmaCyte Biotech's Buy-and-hold return. Our buy-and-hold chart shows how PharmaCyte Biotech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.PharmaCyte Biotech Market Price Analysis
Market price analysis indicators help investors to evaluate how PharmaCyte Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PharmaCyte Biotech shares will generate the highest return on investment. By understating and applying PharmaCyte Biotech stock market price indicators, traders can identify PharmaCyte Biotech position entry and exit signals to maximize returns.
PharmaCyte Biotech Return and Market Media
The median price of PharmaCyte Biotech for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 0.96 with a coefficient of variation of 14.07. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 0.92, and mean deviation of 0.11. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Liquard Thomas of PharmaCyte Biotech subject to Rule 16b-3 | 10/15/2025 |
2 | Will PharmaCyte Biotech Inc. stock reach all time highs in 2025 - July 2025 Earnings Consistent Growth Equity Picks - newser.com | 10/29/2025 |
3 | What Fibonacci levels say about PharmaCyte Biotech Inc. rebound - Weekly Trade Summary Growth Oriented Trading Recommendations - newser.com | 11/04/2025 |
4 | Form 4 PharmaCyte Biotech, Inc. Insider Trading Activity - Stock Titan | 11/18/2025 |
5 | PharmaCyte Biotech Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 12/04/2025 |
6 | PharmaCyte Biotech faces NASDAQ non-compliance notice - MSN | 12/09/2025 |
7 | Disposition of 16875 shares by Abecassis Michael M of PharmaCyte Biotech at 1.02 subject to Rule 16b-3 | 12/12/2025 |
8 | Nuvilex Issues Earnings Results | 12/18/2025 |
About PharmaCyte Biotech Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including PharmaCyte or other stocks. Alpha measures the amount that position in PharmaCyte Biotech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2011 | 2024 (projected) | Dividend Yield | 0.12 | 0.11 | Price To Sales Ratio | 215.39 | 3.2K |
PharmaCyte Biotech Upcoming Company Events
As portrayed in its financial statements, the presentation of PharmaCyte Biotech's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PharmaCyte Biotech's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of PharmaCyte Biotech's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of PharmaCyte Biotech. Please utilize our Beneish M Score to check the likelihood of PharmaCyte Biotech's management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
Build Portfolio with PharmaCyte Biotech
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out PharmaCyte Biotech Backtesting, PharmaCyte Biotech Valuation, PharmaCyte Biotech Correlation, PharmaCyte Biotech Hype Analysis, PharmaCyte Biotech Volatility, PharmaCyte Biotech History and analyze PharmaCyte Biotech Performance. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.